Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers

TLDR

Autologous Preparation Rich in Growth Factors (PRGF) is a novel plasma-based therapy that accelerates wound healing by continuously releasing multiple growth factors such as PDGF‑AB, TGF‑β1, IGF‑I, HGF, VEGF‑A, and EGF. The study aims to characterize PRGF and evaluate its effectiveness in treating chronic cutaneous ulcers through a randomized open‑label controlled pilot trial. The authors characterized the PRGF preparation and conducted a randomized open‑label controlled pilot trial to assess its therapeutic effect on chronic cutaneous ulcers. At eight weeks, PRGF‑treated ulcers achieved a mean 72.94 % surface healing versus 21.48 % in controls (p < 0.05), indicating that topical PRGF is more effective than standard therapy. © 2007 Wiley Periodicals, Inc., J Biomed Mater Res Part B: Appl Biomater 2008.

Abstract

Abstract Autologous Preparation Rich in Growth Factors (PRGF), a small volume of plasma enriched in platelets, is a novel therapeutic strategy for the acceleration of the wound healing of a wide range of tissues because of the continuous release of multiple growth factors, including PDGF‐AB, TGF‐β1, IGF‐I, HGF, VEGF‐A, and EGF. In this article, we have characterized the PRGF preparation and designed a randomized open‐label controlled pilot trial to evaluate the effectiveness of PRGF in the treatment of chronic cutaneous ulcers. Results showed that at 8 weeks, the mean percentage of surface healed in the PRGF group was 72.94% ± 22.25% whereas it was 21.48% ± 33.56% in the control group ( p &lt; 0.05). These results, with the limitations of a pilot study, suggest that topical application of PRGF is more effective than standard therapy in helping a chronic ulcer to heal. © 2007 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 2008